Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Greg Madison, the Company's Chief Executive Officer, will be presenting a company overview, including progress with the commercialization of Auryxia™ (ferric citrate) in the United States, at the Bank of America Merrill Lynch 2015 Health Care Conference, to be held at the Encore at the Wynn in Las Vegas, NV on May 12-14, 2015.
Mr. Madison's presentation will take place on Thursday, May 13th at 5:00 p.m. PT (8:00 p.m. ET). A live audio webcast of Mr. Madison's presentation will be accessible within the Investor Relations section of the Company's website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President, Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail: [email protected]Source: Keryx Biopharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Island Fin Poké Co. Celebrates Earth Day by Sharing Its Sustainable Efforts Toward a Greener Earth
- Arthrex Wins Both Gold and Silver Medals at 2024 Edison Awards
- Port Houston Regular Commission Meeting
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!